Fc-fusion proteins are bioengineered polypeptides that join the crystallizable fragment (Fc) domain of an antibody with another biologically active protein domain or peptide to generate a molecule with unique structure–function properties and significant therapeutic potential. The gamma immunoglobulin (IgG) isotype is often used as the basis for generating Fc-fusion proteins
The global market for Fc Fusion Protein Drug is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Fc Fusion Protein Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Fc Fusion Protein Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Fc Fusion Protein Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Fc Fusion Protein Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Fc Fusion Protein Drug players cover Sanofi, Bristol-Myers Squibb, Regeneron, Bayer and Amgen, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This latest report provides a deep insight into the global Fc Fusion Protein Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Fc Fusion Protein Drug market, with both quantitative and qualitative data, to help readers understand how the Fc Fusion Protein Drug market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
The study segments the Fc Fusion Protein Drug market and forecasts the market size by Type (Brands Drugs and Biosimilar Drugs,), by Application (Autoimmune Disease, Eye Diseases, Diabetes and Hemophilia), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Segmentation by application
Segmentation by region
Middle East & Africa
Major companies covered
Eli Lilly and Company
Chapter 1: Scope of Fc Fusion Protein Drug, Research Methodology, etc.
Chapter 2: Executive Summary, global Fc Fusion Protein Drug market size and CAGR, Fc Fusion Protein Drug market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Fc Fusion Protein Drug revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Fc Fusion Protein Drug revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Fc Fusion Protein Drug market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Sanofi, Bristol-Myers Squibb, Regeneron, Bayer, Amgen, Pfizer, Eli Lilly and Company, Sobi and Kanghong Pharma, etc.
Chapter 14: Research Findings and Conclusion